Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563828 | 0.89 | MEN1 (0.56) | MEN1KMT2ARAB9AOPRM1OPRD1 | |
| SCHEMBL27915147 | 0.87 | OPRM1 (0.55) | MEN1KMT2ARAB9AOPRM1OPRD1 | |
| SCHEMBL13411094 | 0.86 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL2789658 | 0.85 | KDM4E (0.61) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL6161492 | 0.84 | TSHR (0.56) | MEN1KMT2ARAB9AOPRM1OPRD1 | |
| SCHEMBL13993297 | 0.82 | DDB1 (0.46) | MEN1KMT2ARAB9ANPSR1 | |
| SCHEMBL3558511 | 0.82 | ALDH1A1 (0.46) | MEN1KMT2ARAB9ANPSR1 | |
| SCHEMBL2467789 | 0.81 | KMT2A (0.58) | MEN1KMT2ARAB9AOPRD1OPRK1 | |
| SCHEMBL13993260 | 0.80 | SMN1; SMN2 (0.47) | MEN1KMT2ARAB9AOPRD1OPRK1 | |
| SCHEMBL6161497 | 0.79 | TSHR (0.51) | MEN1KMT2ARAB9AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| CN-102186829-A | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD | 2011-09-14 | — | — | CN | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1501467-A4 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
| WO-2005030209-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-07 | — | — | WO | disclosed |
| EP-1501467-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040110793-A1 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2003088908-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | MEN1 3501/4885KMT2A 957/4885RAB9A 1780/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | MEN1 3501/4885KMT2A 957/4885RAB9A 1780/4885 |
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | MEN1 1845/4885KMT2A 3265/4885RAB9A 2354/4885 |
| US-20040110793-A1 | Heterocyclo inhibitors of potassium channel function | KCNH2, KCNN1, KCNJ2 | MEN1 2867/4885KMT2A 1147/4885RAB9A 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.